Nelsen Robert
Director, 10% Owner | Director
8 companies
Insider Signal Score
31
WeakTrades Analyzed
4
12M Win Rate
0.0%
Avg 3M Return
+14.6%
Avg 12M Return
-56.7%
Nelsen Robert is a Director, 10% Owner at LYEL with holdings across 8 companies. Recent SEC Form 4 filings include 9 buys and 15 sells.
Estimated insider holdings value: $319.3M based on current market prices.
Holdings by Company
LYELJun 21, 2021
Current Shares18.21M
Value$258.71M
Net Activity0
Bought: 0Sold: 0
SANAFeb 8, 2024
Current Shares10.67M
Value$36.38M
Net Activity+1.82M
Bought: 1.82MSold: 0
PRMEAug 1, 2025
Current Shares6.23M
Value$18.38M
Net Activity+7.03M
Bought: 7.03MSold: 0
SYRSJul 6, 2016
Current Shares1.81M
Value$181.33
Net Activity+400.0K
Bought: 400.0KSold: 0
VIRMay 30, 2024
Current Shares584.1K
Value$5.12M
Net Activity+1.00M
Bought: 1.00MSold: 0
BEAMMar 31, 2021
Current Shares14.1K
Value$382.9K
Net Activity0
Bought: 0Sold: 0
DNLIJun 2, 2021
Current Shares12.4K
Value$307.4K
Net Activity0
Bought: 0Sold: 0
AGIOMar 6, 2017
Current Shares0
Value-
Net Activity-419,045
Bought: 0Sold: 419.0K
Transaction History
Showing 9 filings
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Director, 10% Owner | Buy | 3,030,300 | $3.30 | $9,999,990.00 | +94.7% | +7.7% | -27.7% | |
| Feb 15, 2024 | PRME Prime Medicine, Inc. | Director, 10% Owner | Buy | 3,200,000 | $6.25 | $20,000,000.00 | New | -13.3% | -63.6% | |
| Feb 8, 2024 | SANA Sana Biotechnology, Inc. | Director, 10% Owner | Buy | 1,818,181 | $5.50 | $9,999,995.50 | +5.4% | +54.1% | -51.5% | |
| Oct 24, 2022 | PRME Prime Medicine, Inc. | Director, 10% Owner | Buy | 800,000 | $17.00 | $13,600,000.00 | +7.0% | +10.1% | -54.9% | |
| Oct 16, 2019 | VIR Vir Biotechnology, Inc. | Director, 10% Owner | Buy | 1,000,000 | $20.00 | $20,000,000.00 | New | - | - | |
| Mar 6, 2017 | AGIO Agios Pharmaceuticals, Inc. | Director | Sell | 40,599 | $50.84 | $2,064,208.82 | -80.8% | - | - | |
| Feb 28, 2017 | AGIO Agios Pharmaceuticals, Inc. | Director | Sell | 243,082 | $49.36 | $11,997,895.83 | -30.1% | - | - | |
| Feb 23, 2017 | AGIO Agios Pharmaceuticals, Inc. | Director | Sell | 135,364 | $49.37 | $6,683,463.66 | -6.2% | - | - | |
| Jul 6, 2016 | SYRS Syros Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 400,000 | $12.50 | $5,000,000.00 | +9.4% | - | - |